30 results about "MiR-122" patented technology

The present invention relate to the use of a combination of an inhibitor of miR-122 and an inhibitor of VLDL assembly, for the treatment of HCV, hyperlipidemia and hypercholesterolemia.

The invention in some aspects relates to methods and compositions for assessing the effectiveness of miRNA inhibitors. In other aspects of the invention, methods and compositions for treating cholesterol related disorders are provided. In one aspect of the invention, miRNA inhibitors against miR-122 and rAAV-based compositions comprising the same are provided.

The invention relates to a liver cancer diagnostic marker composed of blood plasma microRNA (micro ribonucleic acid), a kit containing the marker and a new method for diagnosing liver cancer (in particular early liver cancer). The liver cancer diagnostic marker is composed of a plurality of nucleic acid molecules, wherein each nucleic acid molecule is used for coding at least one microRNA sequence; and preferably, the liver cancer diagnostic marker is composed of nucleic acid molecules for coding hsa-miR-122, hsa-miR-192, hsa-miR-21, hsa-miR-223, hsa-miR-26a, hsa-miR-27a, hsa-miR-801 and hsa-miR-1228. The kit can be applied to diagnosing hepatocellular carcinoma, in particular early hepatocellular carcinoma, or to differentiating the blood plasma of at least one hepatocellular carcinoma sufferer from the blood plasma of at least one healthy individual, and the blood plasma of at least one chronic hepatitis b sufferer or the blood plasma of at least one cirrhosis sufferer.

Disclosed is a preparation method of a fluorescent sensor for detecting microRNA. The preparation method comprises the following steps: preparing polyacrylic acid modified GdF3:Tb3+ nanoparticles through a solvothermal method; preparing a solution of GdF3:Tb3+ nanoparticles coupled to a single oligonucleotide chain probe I through catalytic condensation of EDC and NHS; preparing a fresh solution of colloidal gold nanoparticles through reducing chloroauric acid with sodium citrate; coupling a single oligonucleotide chain probe II to the gold nanoparticles by utilizing combination of sulfydryl groups and gold; and preparing a PBS solution of the fluorescent sensor for detecting microRNA. The invention has advantages that: the preparation method of the fluorescent sensor is simple, and is safe to operate, mild in condition, and low in cost; artificially synthesized hsa-miR-122-5p in a buffer solution can be sensitively and specifically recognized; and the fluorescent sensor has a linear range of 1fM-100pM, and a detection limit of 0.5fM.

The invention discloses application of RNA and carrier in preparation of a product for preventing and / or treating liver cancer. The invention provides a recombinant adenovirus carrier which is a recombinant adenovirus carrier formed by inserting at least one encoding gene of miR-122 into a pDC312-cmv; and the miR-122 refers to RNA shown in a sequence 1 in a sequence table or RNA encoded by a sequence 3 in the sequence table. The experiment proves that the miR-122 encoding genes are introduced into the adenovirus carrier, the adenovirus is purified and is used for performing an animal experiment, the miR-122 and the recombinant adenovirus carrier or adenovirus can obviously suppress the liver cancer caused by chronic hepatitis B infection, and a novel liver cancer treatment medicine can be developed.

The invention relates to the technical field of medical bio-detection and relates to a kit used for detecting the content of hsa-mir-122 in blood plasma or blood serum to early predict hepatocirrhosis developed from chronic hepatitis B and a detection method thereof. At present, there is not existed any effective method for predicting hepatocirrhosis developed from chronic hepatitis B, which brings inconvenience for early prediction and treatment clinically. By comparing health crowd with patients with chronic hepatitis B and comparing the contents of hsa-mir-122 in blood plasma between the patients with chronic hepatitis B in four different disease conditions, the invention finds that the change of the content of has-mir-122 can be used as a means of early prediction of the hepatocirrhosis developed from chronic hepatitis B. The invention provides a kit for detecting the hsa-mir-122 to predict hepatocirrhosis developed from chronic hepatitis B. The kit comprises reverse transcription primer, upstream and downstream primers of Real-time PCR and an amplification system and the like; by clinical trial, the accuracy rate of detection is up to about 85 percent, therefore, the kit can be used for early prediction of hepatocirrhosis developed from chronic hepatitis B.

Provided are methods of treating breast cancer in a subject in need thereof comprising administering to the subject an effective amount of an inhibitor of miR-105 or an inhibitor of miR-122 are provided. Also provided herein are methods of determining a level of miR-105 or a level of miR-122 in a subject that has or is at risk for developing breast cancer. The method includes obtaining a biological sample from the subject and determining a level of miR-105 or a level of miR-122 or a combination thereof in the biological sample, wherein a higher level of miR-105 or miR-122 as compared to a control indicates that the subject has or is at risk of developing breast cancer.

The invention discloses seven serum exosome micro-ribonucleic acids (miRNAs) related to diagnosis and treatment of liver cancer, and applications of the seven serum exosome miRNAs. The invention firstly discovers that hsa-miR-122, hsa-miR-125b, hsa-miR-145, hsa-miR-192, hsa-miR-194, hsa-miR-29a and hsa-miR-106a in serum exosomes can be used as biomarkers of the liver cancer, have a higher diagnostic value, provide a rapid and accurate diagnosis way for clinical use, and enable the diagnosis of the liver cancer to be more convenient and easier to implement. The invention also further discoversmatters for inhibiting specific miRNA, and the matters can inhibit the proliferation / growth of cells with the liver cancer, so that a foundation is laid for the clinic treatment of the liver cancer.

The present invention relates to a kit for diagnosing hepatocellular carcinoma consisting of plasma microRNA, a kit containing the same, and a new method therefor. The marker for diagnosing hepatocellular carcinoma consists of a plurality of nucleic acid molecules, each nucleic acid molecule encoding at least one microRNA sequence, preferably consists of nucleic acid molecules encoding hsa-miR-122, hsa-miR-192, hsa-miR-21, hsa-miR-223, hsa-miR-26a, hsa-miR-27a, hsa-miR-801 and hsa-miR-1228. The kit can be used for diagnosing hepatocellular carcinoma, especially early hepatocellular carcinoma, and also for discriminating plasma of at least one hepatocellular carcinoma patient from that of at east one healthy individual, at east one chronic hepatitis B patient, or at east one cirrhosis patient.

The invention discloses a miRNA composition for detecting breast cancer brain metastases and a kit with same. The miRNA composition comprises miR-10b and one or more of miR-200a, miR-122, miR-21 and miR-181c. The kit comprises forward and reverse primers of the miRNA composition, forward and reverse primers of an external reference U6 RNA, a cerebrospinal fluid RNA extraction system, a reverse transcription reagent, a PCR amplification reagent and a cDNA mixed positive reference product. According to the miRNA composition, a group of miRNAs are adopted as novel breast cancer brain metastases markers, low specificity and low sensitivity caused by tumor heterogeneity are hard to overcome by using a single marker can be alleviated, prognosis effectiveness evaluation of a patient suffering from breast cancer can be effectively improved, and thus clinical treatment can be instructed. The miRNA composition is used for preparing a kit or a biological chip for prognosis inspection on breast cancer by using a fluorescent quantitative / digital PCR method, low specificity and low sensitivity caused by tumor heterogeneity can be avoided, the prognosis effectiveness evaluation of the patient suffering from breast cancer can be effectively improved, and thus clinical treatment can be instructed.

Disclosed is the provision of a method for assisting the detection of pancreatic cancer, the method assisting the detection of pancreatic cancer with high accuracy. In the method for assisting the detection of pancreatic cancer, the amounts of (1) miR-122-5p and (2) at least one miRNA selected from the group consisting of miR-16-5p, miR-19b-3p and miR-25-3p, all of which are contained in a test sample separated from a living body, are used as indicators. A larger amount of miR-122-5p and a smaller amount of at least one miRNA selected from the group consisting of miR-16-5p, miR-19b-3p and miR-25-3p than those in a healthy individual indicates that the living body is more likely to have developed pancreatic cancer.

The invention provides a hepatitis B virus miR-3 and human liver specific miR-122 triple fluorescent quantitative PCR detection kit. The hepatitis B virus miR-3 and human liver specific miR-122 triplefluorescent quantitative PCR detection kit comprises a hepatitis B virus miR-3 reverse transcription primer as shown by SEQ ID NO. 1, a fluorescent probe as shown by SEQ ID NO. 2 and PCR primers as shown by SEQ ID NO. 3 and NO. 4, and can further comprise a human liver specific miR-122 reverse transcription primer as shown by SEQ ID NO. 5, a fluorescent probe as shown by SEQ ID NO. 6 and PCR primers as shown by SEQ ID NO. 7 and NO. 8, and can further comprise an internal reference reverse transcription primer as shown by SEQ ID NO. 9, a fluorescent probe as shown by SEQ ID NO. 10, and PCR primers as shown by SEQ ID NO. 11 and NO. 12. The kit uses a triple fluorescent quantitative PCR method to detect the concentration of hepatitis B virus miR-3 and human liver specific miR-122 in trace (100 micro liters) serum or plasma. The detection method is specific, efficient and sensitive. The kit can be used for monitoring the replication situation of the heptatitis B virus, evaluating the curative effect and prognosis of an antiviral drug and evaluating the liver injury and has an important clinical significance.

The invention provides a vector for expressing and transferring gene with muscle tissue specific expression of phosphoenolpyruvatecarboxykinase (PEPCK) for reducing hyperlipidemia, delaying aging, andimproving reproductive capacity. The vector contains a reconstructed promoter of human alpha-skeletal actin gene, an intron of minute virus of mice (MVM), reconstructed cDNA of human phosphoenolpyruvatecarboxykinase 1 (PCK1), and four human miR-122 target sequences which are connected in series connection. The recombinant vector is mediated by an adeno-associated virus vector, and comprises a type 1 adeno-associated virus and the like.

Disclosed is a method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the method for assisting the highly accurate detection of Alzheimer's disease or mild cognitive impairment. In the method for assisting the detection of Alzheimer's disease or mild cognitive impairment, the amount of at least one miRNA selected from miR-122, miR-144, let-7f, miR-128-3p and miR-107 contained in a test sample separated from a living body is used as an indicator. A larger amount of miR-122 than that in a healthy individual, or a smaller amount of at least one miRNA selected from miR-144, let-7f, miR-128-3p and miR-107 than that in a healthy individual is indicative that the living body is more likely to have developed Alzheimer's disease or mild cognitive impairment.

The invention provides a recombinant adeno-associated virus-mediated X chromosome-linked myotubular myopathy treatment drug. A recombinant adeno-associated virus vector carries a myotubularin gene expression box containing human miR-142-3p and miR-122 target sequences. In-vivo experiments show that the recombinant adeno-associated virus vector can be efficiently introduced into a body to continuously and stably express myotubularin, prolong the survival time of an animal model and recover the growth and the development of the animal model. Results prompt that the recombinant adeno-associated virus vector is expected to be developed into the novel X chromosome-linked myotubular myopathy treatment drug.

The present invention features therapies for the treatment of HCV comprising direct-acting antiviral agents. Preferably, the treatment is administered to an HCV-infected patient who has been tested to determine expression levels of microRNAs such as miR-122 or miR-21. In one aspect, the therapies comprise administering one or more direct acting antiviral agents and, optionally ribavirin, to a subject with HCV infection. For example, the therapies comprise administering to the subject effective amounts of therapeutic agent 1, therapeutic agent 2, an inhibitor of cytochrome P450 (e.g., ritonavir), and ribavirin.

The invention relates to a liver cancer detection primer probe and a kit thereof. The kit comprises a digital PCR premixed solution, a droplet stabilizer, a miRNAs primer probe mixed solution and a stem-loop reverse transcription primer mixed solution for RNA reverse transcription. The miRNAs primer probe mixed solution comprises an upstream primer and a probe which are used for detecting hsa-mir-21, hsa-mir-122, hsa-miR-199a and hsa-miR-1228, and a universal downstream primer used for detecting hsa-mir-21, hsa-mir-122, hsa-miR-199a and hsa-miR-1228. The stem-loop reverse transcription primer mixed solution comprises a stem-loop reverse transcription primer used for reverse transcription of hsa-mir-21, hsa-mir-122, hsa-miR-199a and hsa-miR-1228, wherein hsa-mir-21, hsa-mir-122 and hsa-miR-199a are markers, and hsa-miR-1228 is internal reference. The liver cancer detection kit can quickly, conveniently and accurately detect the expression level of miRNAs serving as liver cancer early diagnosis markers.

The invention relates to a human circulating miR-122 detection method. The method includes: extracting serum total RNA (ribonucleic acid) as a sample, dissolving the sample into distilled water without nuclease, taking part of solution to perform reverse transcription to obtain cDNA, carrying out miR-122 specificity real-time fluorescent quantitative PCR (polymerase chain reaction) to obtain Ct values, and verifying chip reflected results. The human circulating miR-122 detection method has advantages that sensitivity is improved, a new clinical basis is provided for human circulating miR-122 variation under a condition of obesity, and circulating miR-122 level is closely related to obesity, glycoregulation and insulin resistance.

The present invention relates to the treatment of hepatitis C (HCV) infection by the combination treatment with a miR-122 inhibitor and a HCV NS3 / 4A protease inhibitor.

The invention relates to a micro ribonucleic acid 122 (miR-122) probe and a preparation method thereof. The probe consists of three parts: i.e., miR-122, a linking group and an azide group suitable for a click chemical reaction; the probe prepared by combining the three parts does not affect the functions of the miR-122 in hepatocytes; after the probe is combined with a target gene, an affinity group is modified by means of the click chemical reaction, so that the enrichment and detection of the target gene of the miR-122 are realized; therefore, an miR-122 regulatory network of the miR-122 in normal hepatocytes and hepatocellular carcinoma cells can be disclosed by means of the analysis, and a new explanation is provided for the molecular mechanism of the miR-122 in a development process of hepatocellular carcinoma. Compared with the traditional biochemical method, the miR-122 probe has the advantages of being high in specificity, simple and convenient to operate, low in cost, suitable for popularization, and the like. The invention is characterized by providing the miR-122 probe, which is convenient for marking, separation and identification of the miR-122 and the downstream target gene thereof, and the preparation method of the miR-122 probe.

The invention relates to application of a transcription factor forkhead box protein O1 (FOXO1) in regulation of specific micro-ribonucleic acid (RNA) miR-122. Experimental data of the inventor prove that: the FOXO1 can be used as a new regulating factor for the miR-122, and regulates the transcription of a primary transcript of the miR-122 by an interferon-responsive element (IRE) locus bound to a core promoter area of the miR-122, so that the FOXO1 can participate in the regulation of functions of the miR-122. The regulation is influenced by signal path closely related to a nutrition state, as well as the competition of a hepatocyte nuclear factor 4 (HNF4) for the binding of the locus, and the transcription factor FOXO1 can finally participate in the fine regulating process of lipid metabolism.

The present invention relates to the treatment of hepatitis C (HCV) infection by the combination treatment with a miR-122 inhibitor and a HCV NS5A RNA protein inhibitor.